Sight Sciences announced that Reay H. Brown, MD, has joined the company as Chief Medical Officer (CMO).
Dr. Brown is one of the most prolific inventors and innovators in the history of surgical glaucoma. He was the original inventor of trabecular microbypass stenting, which has served as the foundation for the micro-invasive glaucoma surgery (MIGS) industry. Over his career, Dr. Brown has published 90 peer reviewed articles on glaucoma and cataract surgery, and has served in prominent thought leadership positions including as Chairman of the American Society of Cataract and Refractive Surgery’s (ASCRS) Glaucoma Committee and as the Glaucoma Editor of EyeWorld magazine where he still serves on the editorial board. He has received the Senior Achievement Award from the American Academy of Ophthalmology, the 2013 Distinguished Alumnus Award from John Hopkins University (Wilmer Eye Institute), the 2014 Innovator Award from the American Glaucoma Society, and the 2017 Charles Kelman Innovator’s Award.
Dr. Brown remains a practicing board-certified ophthalmologist with more than 30 years of experience, specializing in glaucoma, glaucoma surgery, and cataract surgery. He served as the Director of the Glaucoma Service at Emory Eye Center for 11 years prior to entering private practice as a founding partner of Atlanta Ophthalmology Associates in 1999.
“We are extremely proud to add someone who I consider to be one of the true pioneers in the history of modern ophthalmology to our executive team,” CEO Paul Badawi said in a company news release. “Dr. Brown’s vast experience both as a practicing surgeon and as a prolific product innovator aligns perfectly with our company’s core competencies and, on behalf of everyone at Sight Sciences, we could not be more thrilled about Dr. Brown joining the company and furthering our mission.”
“Dr. Brown has been a major force in the surgical glaucoma space for many years and he is uniquely capable of accelerating Sight Sciences’ mission to transform ophthalmology and optometry by addressing the underlying causes of the world’s more prevalent eye diseases,” added Chief Commercial Officer Shawn O’Neil. “We’re looking forward to working closely with Dr. Brown to bring the OMNI Surgical System to cataract surgeons and glaucoma specialists around the world and to disrupt the dry eye market with TearCare, while keeping an eye on developing new products that address marketplace needs.”
“I am thrilled to join Sight Sciences as Chief Medical Officer,” said Dr. Brown. “I have known the leadership team for many years and have become intimately familiar with the company’s product portfolio as an active user of OMNI in my own practice. Having innovated and worked clinically within Schlemm’s canal for many years, I believe the OMNI System has tremendous potential given its unique ability to comprehensively target all three sources of resistance in the conventional outflow pathway using a single clear corneal incision. I look forward to making improvements to the existing product portfolio whenever possible, developing new products, assisting the clinical and commercial teams in the market with OMNI and TearCare, and contributing to the growing success of the company.”